The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.6M data for 1.1M Compounds and 8.9K Targets. Of those, 1,154K data for 533K Compounds and 4.4K Targets were curated by BindingDB curators.

Advanced Search

86 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRFEBI
Takeda Pharmaceutical Co., Ltd
An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.EBI
University of KwaZulu-Natal
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.EBI
Takeda Pharmaceutical Co., Ltd
Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).EBI
Salk Institute
Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors.EBI
Emory University
In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.EBI
Bristol-Myers Squibb Co.
Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.EBI
South Dakota State University
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.EBI
Bristol-Myers Squibb Research and Development
Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists.EBI
GlaxoSmithKline
Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.EBI
Neurocrine Biosciences Inc
Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.EBI
Eisai Co., Ltd
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.EBI
Neurocrine Biosciences Inc
Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.EBI
GlaxoSmithKline
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.EBI
GlaxoSmithKline
Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.EBI
Eisai Co., Ltd
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.EBI
Bristol-Myers Squibb Co.
Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.EBI
Eisai Co., Ltd
Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF1 receptor antagonists.EBI
Eisai Co., Ltd
Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.EBI
Eisai Co., Ltd
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).EBI
Westfalische Wilhelms-Universitat
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI
Bristol-Myers Squibb Co.
2-Arylpyrimidines: novel CRF-1 receptor antagonists.EBI
Neurogen Corporation
Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.EBI
Neurocrine Biosciences Inc
Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.EBI
Neurocrine Biosciences Inc
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.EBI
Salk Institute
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.EBI
DuPont Pharmaceuticals Company
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.EBI
DuPont Pharmaceuticals Company
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF¿?) receptor antagonists.EBI
Minase Research Institute
Lead diversification. Application to existing drug molecules: mifepristone 1 and antalarmin 8.EBI
Pfizer Inc
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.EBI
Pfizer Inc
Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF¿?) receptor antagonists.EBI
Minase Research Institute
6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.EBI
Minase Research Institute
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.EBI
Neurogen Corporation
Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.EBI
Pfizer Inc
Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.EBI
Takeda Pharmaceutical Co., Ltd
Spiroindolones, a potent compound class for the treatment of malaria.EBI
Swiss Tropical and Public Health Institute
Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).EBI
Bristol-Myers Squibb Research & Development
Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.EBI
Pfizer Inc
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.EBI
Bristol-Myers Squibb Co.
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI
Bristol-Myers Squibb Co.
The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.EBI
Neurogen Corporation
Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.EBI
Pfizer Inc
An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.EBI
Pharmaceutical Research Institute
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.EBI
Neurocrine Biosciences Inc
Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.EBI
Pharmaceutical Research Institute
Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.EBI
Pharmaceutical Research Institute
Optimization of CRF1R binding affinity of 2-(2,4,6-trichlorophenyl)-4-trifluoromethyl-5-aminomethylthiazoles through rapid and selective parallel synthesis.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.EBI
Neurocrine Biosciences Inc
Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.EBI
Neurocrine Biosciences Inc
Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.EBI
Neurocrine Bioscience, Inc.
Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.EBI
Neurocrine Biosciences Inc
N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.EBI
Bristol-Myers Squibb Pharma Research Laboratories
Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.EBI
Neurocrine Biosciences Inc
New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.EBI
Central Pharmaceutical Research Institute
2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.EBI
Neurocrine Biosciences Inc
Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists.EBI
Neurocrine Biosciences Inc
Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists.EBI
Neurocrine Biosciences Inc
2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel crf-1 receptor antagonists.EBI
Neurogen Corporation
3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.EBI
Neurogen Corporation
Arylamidrazones as novel corticotropin releasing factor receptor antagonists.EBI
TBA
1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF(1)) receptor antagonist activities.EBI
Neurocrine Biosciences Inc
Discovery of a 7-arylaminobenzimidazole series as novel CRF1 receptor antagonists.EBI
Takeda Pharmaceutical Company Ltd
Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity.EBI
The University of Wollongong
Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.EBI
DuPont Pharmaceuticals Company
Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists.EBI
DuPont Pharmaceuticals Company
4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists.EBI
DuPont Pharmaceuticals Company
Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.EBI
DuPont Pharmaceuticals Company
Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.EBI
DuPont Pharmaceuticals Company
Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.EBI
DuPont Pharmaceuticals Company
Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.EBI
Warner-Lambert Company
Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.EBI
Pfizer Inc
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.EBI
Neurocrine Biosciences Inc
Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists.EBI
Neurocrine Biosciences Inc
Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF?) receptor antagonists.EBI
Bristol-Myers Squibb Co.
Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.EBI
Takeda Pharmaceutical Company Ltd.
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.EBI
University of KwaZulu-Natal
Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.EBI
South Dakota State University
Synthesis and anticholinesterase activities of novel 1,3,4-thiadiazole based compounds.BDB
University of Life Sciences
Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents.BDB
Argonne National Laboratory